[Federal Register Volume 62, Number 85 (Friday, May 2, 1997)]
[Notices]
[Pages 24119-24120]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-11442]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Drug Abuse Advisory Committee.

[[Page 24120]]

    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA regulatory issues.
    Date and Time: The meeting will be held on June 9 and 10, 1997, 
8:30 a.m. to 5:30 p.m.
    Location: Holiday Inn--Bethesda, 8120 Wisconsin Ave., Bethesda, MD.
    Contact Person: Karen M. Templeton-Somers or John Schupp, Center 
for Drug Evaluation and Research (HFD-21), Food and Drug 
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12535. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: On June 9, 1997, the committee will discuss ways in which 
the labeling for smoking cessation products could be made more 
clinically useful. Public response to this topic is solicited. Please 
submit your response to Docket No. 97N-0149, entitled ``Reevaluation of 
Labeling of Smoking Cessation Products,'' to the Dockets Management 
Branch (HFA-305), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857. In order for comments to be summarized and sent to 
the Drug Abuse Advisory Committee prior to the June 9, 1997, meeting, 
they must be received by Dockets Management Branch by May 13, 1997. The 
docket will remain open for additional comments until July 11, 1997. On 
June 10, 1997, the committee will discuss topics in clinical trial 
design for medications used to treat cocaine abuse.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by May 27, 1997. 
Oral presentations from the public will be scheduled between 
approximately 8:30 a.m. to 9:30 a.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before May 27, 1997, and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 24, 1997.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 97-11442 Filed 5-1-97; 8:45 am]
BILLING CODE 4160-01-F